Literature DB >> 6480822

Cryoprecipitation of an anti-Pr2 monoclonal IgM cold agglutinin in the presence of GM3 ganglioside.

P Yeni, M L Harpin, B Habibi, A Billecocq, M J Morelec, J P Clauvel, F Danon, N Baumann, J C Brouet.   

Abstract

The mechanism of cryoprecipitation of a monoclonal IgM kappa cryoglobulin (Mou) with a cold agglutinin activity of Pr2 specificity has been studied. By immunodiffusion this cryoglobulin reacted (by its Fab' fragment) with micellar GM3, a ganglioside bearing the Pr2 antigenic determinant. In contrast to previous reports that indicated a possible temperature dependent self-association of IgM molecules via an immunological interaction leading to cold precipitation, we could not detect any affinity of this cryoglobulin for IgM when we used passive hemagglutination or an indirect enzyme-linked immunosorbent assay (ELISA). However, a GM3-like ganglioside could be extracted, by drastic methods, from the cryoglobulin studied at 22 degrees C, whereas no GM3 was extracted from two control cryoglobulins. Some minor gangliosides (representing less than 25% of total amount of bound gangliosides) were also extracted from Mou cryoglobulin and these gangliosides were shown to crossreact with GM3, as they specifically bind to Mou cryoglobulin by ELISA. After cryoprecipitation the serum still contained a monoclonal anti-Pr2 IgM kappa. A GM3-like ganglioside could be extracted from this purified IgM, and cryoprecipitability could be induced by the addition of a minute amount of micellar GM3. These results suggest that Mou cryoglobulin circulates as an immune complex and that cryoprecipitation may depend on unique IgM-GM3 (or IgM-GM3 cross-reacting gangliosides) complexes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480822      PMCID: PMC425282          DOI: 10.1172/JCI111525

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Characterization of a human macroglobulin. V. A Waldenström macroglobulin with antibody activity.

Authors:  H Metzger
Journal:  Proc Natl Acad Sci U S A       Date:  1967-05       Impact factor: 11.205

2.  A new rapid method for genetic typing of human immunoglobulins.

Authors:  G N Vyas; H H Fudenberg; H M Pretty; E R Gold
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

3.  Binding properties of a Waldenström macroglobulin antibody.

Authors:  M J Stone; H Metzger
Journal:  J Biol Chem       Date:  1968-11-25       Impact factor: 5.157

4.  Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability.

Authors:  M Meltzer; E C Franklin
Journal:  Am J Med       Date:  1966-06       Impact factor: 4.965

5.  Lipid patterns of embryonal carcinoma cell lines and their derivatives: changes with differentiation.

Authors:  M J Coulon-Morelec; M H Buc-Caron
Journal:  Dev Biol       Date:  1981-04-30       Impact factor: 3.582

6.  Isolation and characterization of a trisialoganglioside from mouse brain, containing 9-O-acetyl-N-acetylneuraminic acid.

Authors:  R Ghidoni; S Sonnino; G Tettamanti; N Baumann; G Reuter; R Schauer
Journal:  J Biol Chem       Date:  1980-07-25       Impact factor: 5.157

7.  Demonstration of I-anti-I interaction in a precipitin system.

Authors:  T Feizi; W L Marsh
Journal:  Vox Sang       Date:  1970-04       Impact factor: 2.144

8.  [Extraction of plasma lipids preserving antigenic properties of proteins and allowing quantitation of gangliosides by neuraminic acid determination (author's transl)].

Authors:  S Albouz; J Galli; R Bourdon; N Baumann
Journal:  Ann Biol Clin (Paris)       Date:  1979       Impact factor: 0.459

9.  The use of Sep-Pak C18 cartridges during the isolation of gangliosides.

Authors:  M A Williams; R H McCluer
Journal:  J Neurochem       Date:  1980-07       Impact factor: 5.372

10.  Papain digestion fragments of human IgM globulins.

Authors:  C Mihaesco; M Seligmann
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.